XENE Earnings Prediction
The chart below shows how XENE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, XENE sees a -1.30% change in stock price 10 days leading up to the earnings, and a -5.05% change 10 days following the report. On the earnings day itself, the stock moves by +0.44%. This data can give you a slight idea of what to expect for the next quarter's release.
XENE Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.81
-10.96%
8.00%
No Data Available
XENE Earnings Analysis
Xenon Pharmaceuticals Inc Corporation (XENE.O) Earnings Conference Call
Positive
Cash and Marketable Securities Decline: As of September 30, 2024, we had cash and cash equivalents and marketable securities of $803.3 million compared to $930.9 million as of December 31, 2023.
Sufficient Cash for Operations: Based on current operating plans, including the completion of the azetukin er Phase 3 epilepsy studies and fully supporting late-stage clinical development of azetukin er in MDD, we anticipate having sufficient cash to fund operations into 2027.
Ion Channel Therapeutics Progress: We have made significant progress over the past quarter, consistent with our overall strategy of being at the forefront of discovery and development of ion channel therapeutics.
Unmatched Kv7 Leadership: Xenon's leadership position in the Kv7 field is unmatched as azetukin er represents the only highly potent and selective Kv7 potassium channel opener in clinical development for multiple indications that is backed by long-term efficacy and safety data in patients living with epilepsy and encouraging proof-of-concept data in patients with major depressive disorder.
Seizure Reduction Improvement: We are excited to be able to communicate that we have seen improved seizure reduction over time for those that stay on drug, just as a reminder.
Negative
Cash and Marketable Securities Decline: As of September 30, 2024, we had cash and cash equivalents and marketable securities of $803.3 million compared to $930.9 million as of December 31, 2023.
Sufficient Cash for Operations: Based on current operating plans, including the completion of the azetukinler Phase 3 epilepsy studies and fully supporting late-stage clinical development of azetukinler in MDD, we anticipate having sufficient cash to fund operations into 2027.
Pivotal Year Ahead: We anticipate that 2025 will be a pivotal and transformational year for Xenon with several important milestones on the horizon.
Ion Channel Therapeutics Progress: We have made significant progress over the past quarter, consistent with our overall strategy of being at the forefront of discovery and development of ion channel therapeutics.
Unmatched Kv7 Leadership: Xenon's leadership position in the Kv7 field is unmatched as azetukinler represents the only highly potent and selective Kv7 potassium channel opener in clinical development for multiple indications that is backed by long-term efficacy and safety data in patients living with epilepsy and encouraging proof-of-concept data in patients with major depressive disorder.
XENE FAQs
How does XENE typically perform around its earnings report dates?
Is Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
XENE Earning Call Sentiment
Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
XENE.O
-3.37%Positive
The earnings call presents mixed signals. Financial performance shows cash reserves decreasing by 14%, raising concerns about funding future operations. Unclear management responses in the Q&A raise red flags, particularly regarding the clinical profile of key candidates. Despite sufficient cash to fund operations into 2027 and positive NDA submission plans, competitive pressures and regulatory risks loom large. Market cap of $2.8 billion suggests moderate volatility. Overall sentiment is negative, with stock likely to decline 2% to 8% over the next two weeks due to financial risks and management's evasive communication.
